Objective: Studies investigating the associations between CX3CR1 genetic polymorphisms and age-related macular degeneration (AMD) have reported controversial results. Therefore, this meta-analysis aims to clarify the effects of CX3CR1 T280M and V249I polymorphisms on AMD risk. Design: Meta-analysis. Participants: Results from six studies were pooled in the meta-analysis. Methods: Relevant studies were selected through an extensive search of PubMed, EMBASE, and the Web of Science databases. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using random-effects model. Results: Six studies with were included in this systematic review and meta-analysis. There was no significant association between CX3CR1 T280M polymorphism and risk of AMD under all genetic models (TT vs CC/CT: OR = 1.57, 95% Cl = 0.87-2.84; CC vs TT/CT: OR = 0.75, 95% Cl = 0.54-1.06; TT vs CC: OR = 0.58, 95% Cl = 0.30-1.144; CT vs CC: OR = 1.25, 95% Cl = 0.91-1.70). The CX3CR1 V249I polymorphism also did not significantly affect the AMD risk (AA vs GG/AG: OR = 1.23, 95% Cl = 0.98-1.55; AG/AA vs GG: OR = 0.56, 95% Cl = 0.29-1.07; AA vs GG: OR = 1.43, 95% Cl = 0.97-2.09; AG vs GG: OR = 1.07, 95% Cl = 0.85-1.36). Conclusions: This meta-analysis suggested that CX3CR1 T280M and V249I polymorphisms may not be associated with an increased risk of AMD based on current published data. Given the limited sample size, the finding on CX3CR1 polymorphisms needs further investigation.